Nanobiotix (NASDAQ:NBTX) Shares Gap Down – Here’s Why

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report)’s share price gapped down prior to trading on Tuesday. The stock had previously closed at $30.66, but opened at $27.90. Nanobiotix shares last traded at $27.36, with a volume of 7,020 shares traded.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on NBTX. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research report on Thursday, October 15th. Guggenheim assumed coverage on shares of Nanobiotix in a report on Tuesday, September 15th. They set a “buy” rating and a $64.00 target price on the stock. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $46.67.

Check Out Our Latest Research Report on Nanobiotix

Nanobiotix Stock Performance

The company has a 50-day moving average of $30.13 and a 200 day moving average of $34.24.

Institutional Trading of Nanobiotix

An institutional investor recently bought a new stake in Nanobiotix stock. Aquatic Capital Management LLC acquired a new position in Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 2,118 shares of the company’s stock, valued at approximately $66,000. 38.81% of the stock is currently owned by hedge funds and other institutional investors.

About Nanobiotix

(Get Free Report)

Nanobiotix is a French biotechnology company developing nanoparticle-based treatments for cancer. Founded in 2003, the company focuses on using nanomedicine to enhance the effects of established cancer therapies, particularly radiation therapy. Its lead product candidate, NBTXR3, is made from hafnium oxide nanoparticles and is designed to be injected directly into a tumor. When exposed to radiation, the particles are intended to increase damage to cancer cells while limiting the effect on surrounding healthy tissue.

Read More

Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.